TailorMed

AI assists a workflow platform rather than constituting it. The core product is a financial navigation system that centralizes roughly 6,000 assistance program resources, verifies benefits through a clearinghouse, calculates remaining deductible and cost exposure, and manages enrollment. The AI layer is real but bounded: the company describes surfacing assistance programs using automation and AI, intelligently matching patients to opportunities, and an in context generative AI assistant built for navigators. A separate service arm explicitly combines AI, automation, and human expert teams. Buyers should size this as workflow software with AI matching, not an autonomous system.

A human navigator is the actor throughout and the design says so. The platform populates work queues, prioritizes patients by assistance opportunity, pre fills program forms from live EHR data, and tracks application status, with the navigator reviewing and submitting. That is the appropriate structure given the outputs are benefit enrollments with financial and eligibility consequences for the patient. The generative AI assistant is positioned as helping navigators search programs and surface eligible patients rather than acting for them.

No model, architecture, or matching methodology disclosure was located. The AI is described functionally as matching, surfacing, and assisting, with no account of how eligibility matching is computed or evaluated, which matters because a missed match means a patient does not receive assistance they qualified for.

Evidence is customer case studies at named institutions rather than measured study. The company publishes case studies with a large not for profit health system, a regional health system, and a named oncology group covering standardization of financial navigation and program optimization, and describes serving health systems, oncology practices, infusion centers, and pharmacies. What is absent from public materials is quantified outcome data, meaning dollars of assistance secured per patient, enrollment rates versus baseline, or effect on treatment abandonment, which is the outcome that actually matters in medication affordability.

No published PHI framework was located. The platform handles an unusually sensitive combination, since it processes clinical treatment plans alongside patient financial circumstances and insurance status in order to determine assistance eligibility, and it pulls live EHR data to populate program forms submitted to third party foundations and manufacturers. Where that data goes on submission is a question a buyer should map explicitly.

No HIPAA or BAA commitment was located in public materials, though business associate status is structurally required given deep EHR integration at health systems and oncology practices.

No SOC 2, HITRUST, or ISO 27001 attestation was located, and no trust center was found.

No FDA pathway applies. The platform operates on financial assistance, benefits, and enrollment workflow with no clinical decision surface. The regulatory considerations that do apply are copay assistance and manufacturer program rules, including federal anti kickback and beneficiary inducement constraints that govern which patients may receive which forms of assistance, and no public position on that compliance surface was located.

No governance framework or bias evaluation was located, and the equity question here is direct rather than abstract. A system that prioritizes patients by assistance opportunity is allocating a scarce navigator's time, and if prioritization favors higher dollar opportunities it may systematically underserve patients with smaller but still decisive financial barriers. Nothing published addresses how prioritization is weighted.

Integration is substantive and is what distinguishes the platform from a program database. The company states it is deeply integrated with health system IT, uses live EHR data to instantly populate program forms and eliminate manual entry, verifies benefits through a clearinghouse, and updates the pharmacy module automatically based on the patient's treatment plan and treatment status. Pulling the treatment plan to time drug availability is a real clinical data dependency rather than a demographic feed. No named EHR integrations or standards were located.

No hosting, tenancy, or data residency disclosure was located.

No published pricing across any of the product lines. The commercial structure is worth understanding before contracting because the company monetizes on multiple sides: a care team platform sold to providers, a patient facing product, a tech enabled service arm, and separately digital solutions sold to life sciences companies to improve access and time to therapy across its network. A provider should understand what manufacturer relationships exist alongside their own deployment.

Broad across the medication access surface, spanning health systems, oncology practices, infusion centers, and pharmacies, with life sciences companies as a separate customer class. Functional coverage runs from identifying financially at risk patients through enrollment, free and replacement drug inventory management, and adherence support. Oncology and infusion are the evident center of gravity given the case studies and the treatment plan driven pharmacy workflow, which is where high cost specialty medications concentrate.